Advertisement

β- and α-Cell Dysfunction in Subjects Developing Impaired Glucose Tolerance

Outcome of a 12-Year Prospective Study in Postmenopausal Caucasian Women

  1. B. Ahrén
  1. From the Department of Clinical Sciences in Lund, Division of Medicine, Lund University, Lund, Sweden
  1. Corresponding author: Bo Ahrén, bo.ahren{at}med.lu.se

Abstract

OBJECTIVE— This study assessed insulin and glucagon secretion in relation to insulin sensitivity in Caucasian women who develop impaired glucose tolerance (IGT) versus those who maintain normal glucose tolerance (NGT) over a 12-year period.

RESEARCH DESIGN AND METHODS— At baseline and after 3, 8, and 12 years, glucose tolerance (75-g oral glucose tolerance test), insulin sensitivity (euglycemic-hyperinsulinemic clamp), and insulin and glucagon secretion (2- to 5-min responses to 5 g arginine i.v. at fasting, 14 and >25 mmol/l glucose) were determined in 53 healthy Caucasian women (aged 58 years at baseline) who all had NGT at baseline.

RESULTS— During the 12-year period, 26 subjects developed IGT, whereas the remaining 27 subjects maintained NGT throughout the 12-year period. Subjects developing IGT had lower insulin sensitivity than those maintaining NGT in the tests preceding diagnosis of IGT (P ≤ 0.05). When judged in relation to insulin sensitivity, β-cell glucose sensitivity and maximal insulin secretion were lower in those who later developed IGT than in those maintaining NGT at all tests (P ≤ 0.05). Furthermore, subjects who developed IGT had defective suppression of glucagon secretion by glucose in the test preceding diagnosis of IGT when they still had NGT (P ≤ 0.05).

CONCLUSIONS— β- and α-cell dysfunction are evident several years before diagnosis of IGT, and islet dysfunction is manifested as impaired glucose sensitivity of the β- and α-cells and reduced maximal insulin secretion.

Footnotes

  • Published ahead of print at http://diabetes.diabetesjournals.org on 18 December 2008.

    Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

    The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Accepted December 11, 2008.
    • Received August 24, 2008.
| Table of Contents

This Article

  1. Diabetes March 2009 vol. 58 no. 3 726-731
  1. » Abstract
  2. All Versions of this Article:
    1. db08-1158v1
    2. 58/3/726 most recent

Social Bookmarking

Advertisement